Research and Markets: Clinical Trial Recruitment Strategies in Oncology - Enabled Patient Management Systems will Reduce R

DUBLIN--(BUSINESS WIRE)-- Research and Markets (http://www.researchandmarkets.com/research/fd0de1/clinical_trial_rec) has announced the addition of the "Clinical Trial Recruitment Strategies in Oncology - Online Recruitment Methods and Use of IT - enabled Patient Management Systems will Reduce Recruitment Time and Cost" report to their offering.

Clinical Trial Recruitment Strategies in Oncology - Enabled Patient Management Systems will Reduce Recruitment Time and Cost

Clinical Trial Recruitment Strategies in Oncology - Online Recruitment Methods and Use of IT - enabled Patient Management Systems Will Reduce Recruitment Time and Cost, which provides insights into recruitment strategies, challenges and solutions for on-time recruitment in oncology trials. The report also examines case studies to illustrate enhanced recruitment in a shorter time. The report provides an in-depth analysis of the trials conducted by major pharmaceutical companies for the top five oncology therapeutic indications, which are breast cancer, colorectal cancer, prostate cancer, lung cancer and brain cancer.

Increasing Focus of Major Pharmaceutical Companies on Oncology Markets

Major pharmaceutical companies conduct clinical trials in many therapeutic areas, such as cardiovascular diseases, infectious diseases, oncology, metabolic disorders and central nervous system disorders.

The authors analysis finds that oncology is responsible for the most trials across the globe. The major pharmaceutical companies conducted more clinical trials in oncology than in other therapy areas during the period between 2005 and 2010.

The figure below shows the number of trials by major pharmaceutical companies such as AstraZeneca, Bristol-Myers Squibb, Roche, Merck and Sanofi Aventis, and clearly demonstrates the prevalence of oncology trials.

Clinical Trial Recruitment Strategies in Oncology, Global, Clinical Trials by Major Pharmaceutical Companies, 2005-2010 Pharmaceutical companies are doing extensive research in oncology trials compared to other therapeutic areas. The higher incidence rates in cancer and increase in severity are the major drivers.

The authors estimated that the cost of one trial is approximately $2.28m. As the average time of an oncology trial is 4.5 years, the average cost of a trial is $0.5m per year.

Outsourcing Clinical Trial Patient Recruitment Will Help Companies to Save Cost and Time

Outsourcing of clinical trials to clinical research organizations (CROs) is becoming a major trend for pharmaceutical companies to reduce the time and cost of a trial. Outsourcing can be done for the whole trial or for part of a trial, which can be the start-up Phase, the ongoing part of the trial, or the data management part of the trial.

Outsourcing a part of the trial helps with time management and relieves the sponsor to allow them to plan better for the other important parts of the trial, which then permits those to be managed in a better way.

There are many CROs who work actively for patient recruitment. They manage their own online database of investigators, as well as the hospitals, clinics and private physicians and professionally active physicians. They have an idea about the type of patients to be obtained and about the kind and number of patients the site can provide for. Examples of CROs are D. Anderson and Company, Max Neeman, Clinlogix, PPD, and Quintiles.

Key Topics Covered:

1 Table of Contents

2 Clinical Trial Recruitment Strategies in Oncology: Introduction

3 Clinical Trials Overview

4 Patient Recruitment Process for Clinical Trials

5 Online Recruitment: Electronic Data Capture in Clinical Trials

6 Profiles of Major CROs in Patient Recruitment

7 Appendix

For more information visit http://www.researchandmarkets.com/research/fd0de1/clinical_trial_rec



CONTACT:

Research and Markets
Laura Wood, Senior Manager,
[email protected]
U.S. Fax: 646-607-1907
Fax (outside U.S.): +353-1-481-1716

KEYWORDS:

INDUSTRY KEYWORDS:   Technology  Internet  Health  Clinical Trials

MEDIA:

Logo
 Logo

Suggested Articles

Six pharmaceutical execs are set to head to Washington next week for pricing hearings at the House Committee on Oversight and Reform. 

After sifting through the data, one analyst figures the latest Opdivo-Keytruda showdown in kidney cancer might come down to commercial execution.

Biogen is giving former chief finance officer Jeff Capello a multimillion-dollar cash payment plus other severance benefits.